Related Experiment Video

Updated: May 20, 2026

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins
10:05

Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins

Published on: August 7, 2014

Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel

Kaija-Leena Kolho1, Elsa Valtonen, Hanne Rintamäki

  • 1Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. kaija-leena.kolho@helsinki.fi

Scandinavian Journal of Gastroenterology
|July 4, 2012
PubMed

Insights

Soluble urokinase plasminogen activator receptor (suPAR) shows limited value in pediatric inflammatory bowel disease (IBD). While glucocorticoids reduced suPAR levels, it did not correlate with intestinal inflammation or therapeutic response to TNF-α-antagonist.

Area of Science:

  • Pediatric Gastroenterology
  • Inflammation Biomarkers
  • Immunology

Background:

  • Early monitoring of therapeutic response in pediatric inflammatory bowel disease (IBD) remains a clinical challenge.
  • Conventional blood inflammatory markers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can be low in severe pediatric IBD.
  • Soluble urokinase plasminogen activator receptor (suPAR) has emerged as a potential inflammatory marker in adult IBD.

Purpose of the Study:

  • To evaluate the performance of suPAR as a biomarker in pediatric IBD.
  • To assess the association of suPAR with disease type (Crohn's disease vs. ulcerative colitis) and inflammatory markers.
  • To investigate the effect of glucocorticoid and TNF-α-antagonist therapies on suPAR levels in pediatric IBD.

Main Methods:

  • Prospective study of pediatric IBD patients initiating glucocorticoid (n=19) or TNF-α-antagonist (n=16) therapy.
  • Measurement of suPAR levels at the start of therapy.
  • Correlation analysis of suPAR with ESR, CRP, and fecal calprotectin (FC).

Main Results:

  • suPAR levels were generally low in pediatric IBD patients, irrespective of disease type.
  • Glucocorticoid therapy led to a significant decline in suPAR levels (p < 0.01).
  • TNF-α-antagonist therapy did not affect suPAR levels. suPAR did not correlate with ESR, CRP, or FC.

Conclusions:

  • suPAR levels in pediatric IBD are low and do not reflect the degree of intestinal inflammation as assessed by FC.
  • While glucocorticoids reduce suPAR, this change does not reliably indicate therapeutic response.
  • suPAR demonstrates limited utility for assessing systemic inflammatory responses in pediatric IBD patients.
Abstract

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance07:32

An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance

Published on: December 3, 2020

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...